《大行報告》大和上調京東健康(06618.HK)目標價至77元 評級「買入」
大和發表研究報告指,市場監管總局發布《藥品網絡銷售監督管理辦法》,規範藥品網絡銷售,新規將消除市場上的監管不確定性。
由於當局提供3個月的寬限期,大和表示,相信京東健康(06618.HK)管理層將靈活應對監管要求變化,公司表示已針對網絡藥品銷售監管的不同場景制定後備計劃,預期監管調整對其業務影響不大。
大和又指,由於第三方銷售業務為公司貢獻較高利潤的收入來源,相信新規出台後市場對京東毛利率的擔憂也可能緩解,重申「買入」評級,目標價自75元上調至77元,並將2022至2024年的非國際財務報告準則下盈利預測上調2%至9%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.